Last reviewed · How we verify

NCT06332911: TEVAR

Shockwave™Peripheral Intravascular Lithotripsy Balloon for Advanced Endovascular Aortic Repair

Recruiting now Last updated 23 May 2025
What this trial tests

trial testing Shockwave™ Peripheral Intravascular Lithotripsy Balloon M5+ in Thoracoabdominal Aortic Aneurysm, Without Mention of Rupture in 30 participants. Currently enrolling.

Timeline
19 May 2025
Primary endpoint
30 May 2026
30 May 2027

Quick facts

Lead sponsorRede Optimus Hospitalar SA
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment30
Start date19 May 2025
Primary completion30 May 2026
Estimated completion30 May 2027
Sites5 locations across Italy, Switzerland, Germany

Drugs / interventions tested

Conditions studied

Sponsor

Rede Optimus Hospitalar SA

Who can join

18 and older, any sex, with Thoracoabdominal Aortic Aneurysm, Without Mention of Rupture or Abdominal Aortic Aneurysm Without Rupture. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Shockwave TEVAR is a nonrandomized, prospective, international, multi-center, PMCF, obervational study. The aim of this study is to evaluate the outcomes of the Shockwave™ Peripheral Intravascular Lithotripsy Balloon (Shockwave Medical Inc.) in the routine treatment of hostile iliac accesses during TEVAR and F/BEVAR.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Thoracoabdominal Aortic Aneurysm, Without Mention of Rupture

Currently open trials in the same condition.

Other Rede Optimus Hospitalar SA trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06332911.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing